68166 stocks real-time data.
All stocks today

Stock quotes

Stock market live

Historical stock prices

Stocks market capitalization

Dividend stocks

Stock earnings

Stock revenue

Stock ratings. Where to invest?

Regeneron Pharmaceuticals, Inc. revenue reports

Regeneron Pharmaceuticals, Inc. financial reports, Regeneron Pharmaceuticals, Inc. annual revenue in 2019. When does Regeneron Pharmaceuticals, Inc. report revenue?
Add to widgets
Added to widgets
Report date Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and Change (%)
Comparing current quartal report this year to quartal report last year.
31/12/2018 1 927 797 000 $ +21.82 % ↑ 820 353 000 $ +372.77 % ↑
30/09/2018 1 663 496 000 $ +10.85 % ↑ 594 655 000 $ +53.14 % ↑
30/06/2018 1 608 022 000 $ +9.38 % ↑ 551 412 000 $ +42.21 % ↑
31/03/2018 1 511 485 000 $ - 477 980 000 $ -
31/12/2017 1 582 447 000 $ - 173 519 000 $ -
30/09/2017 1 500 673 000 $ - 388 317 000 $ -
30/06/2017 1 470 116 000 $ - 387 744 000 $ -
Show:
to

Regeneron Pharmaceuticals, Inc. financial report charts

Regeneron Pharmaceuticals, Inc. quarterly report dates

31/12/2018 30/09/2018 30/06/2018 31/03/2018 31/12/2017 30/09/2017 30/06/2017
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
1 810 625 000 $ 1 553 127 000 $ 1 516 361 000 $ 1 396 587 000 $ 1 476 707 000 $ 1 396 441 000 $ 1 367 195 000 $
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
117 172 000 $ 110 369 000 $ 91 661 000 $ 114 898 000 $ 105 740 000 $ 104 232 000 $ 102 921 000 $
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
1 927 797 000 $ 1 663 496 000 $ 1 608 022 000 $ 1 511 485 000 $ 1 582 447 000 $ 1 500 673 000 $ 1 470 116 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
1 825 549 000 $ 1 546 126 000 $ 1 496 998 000 $ 1 425 327 000 $ 1 475 374 000 $ 1 439 167 000 $ 1 356 616 000 $
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
718 058 000 $ 626 923 000 $ 622 188 000 $ 567 231 000 $ 538 811 000 $ 559 926 000 $ 550 312 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
820 353 000 $ 594 655 000 $ 551 412 000 $ 477 980 000 $ 173 519 000 $ 388 317 000 $ 387 744 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
601 253 000 $ 556 972 000 $ 529 289 000 $ 498 586 000 $ 527 983 000 $ 529 749 000 $ 509 975 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
1 092 567 000 $ 926 204 000 $ 894 173 000 $ 829 356 000 $ 937 896 000 $ 836 515 000 $ 816 883 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
6 447 600 000 $ 5 719 583 000 $ 4 814 917 000 $ 4 544 732 000 $ 4 335 030 000 $ 4 135 742 000 $ 3 860 051 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
11 734 500 000 $ 10 805 613 000 $ 9 951 980 000 $ 9 372 696 000 $ 8 764 286 000 $ 8 701 215 000 $ 8 106 373 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
1 480 200 000 $ 1 100 343 000 $ 930 376 000 $ 1 031 991 000 $ 812 733 000 $ 792 065 000 $ 744 313 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
- - - - - - -
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
2 809 900 000 $ 2 192 152 000 $ 1 683 518 000 $ 1 624 952 000 $ 1 409 580 000 $ 1 378 944 000 $ 1 267 850 000 $
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
- - - - - - -
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
- - - - - - -
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
8 757 300 000 $ 7 868 300 000 $ 7 186 426 000 $ 6 567 644 000 $ 6 144 078 000 $ 6 051 593 000 $ 5 520 738 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
728 831 000 $ 452 961 000 $ 394 565 000 $ 618 743 000 $ 566 949 000 $ 414 832 000 $ -30 570 000 $

Last revenue report of Regeneron Pharmaceuticals, Inc. was 31/12/2018. According to last financial report total revenue in Regeneron Pharmaceuticals, Inc. was 1 927 797 000 US dollar and changed by +21.82% since last year. Net income in Regeneron Pharmaceuticals, Inc. was 820 353 000 $ in last quartal, net income changes to +372.77%.

Regeneron Pharmaceuticals, Inc. stocks data

Regeneron Pharmaceuticals, Inc. financials